Russian drug patent owners are being forced to come up with novel solutions to combat generic manufacturers trying to clear the way for competitor medicines.
US presidential candidates Bernie Sanders and Cory Booker have tabled a bill that would force drug companies to adhere to government-set prices-or risk losing patent exclusivity.
The Russian government has endorsed legislation that would allow it to employ compulsory drug licensing in emergencies.
A Chinese state-owned chemical firm is suing US crop protection products company Atticus for patent infringement.
Novartis has agreed to buy the Japanese business of South African generics manufacturer Aspen Pharmacare for a potential €400 million.
Pfizer and Indian drugmaker Sun Pharmaceuticals have agreed to settle patent litigation over a generic version of Pfizer’s leukaemia drug, Bosulif.
German pharmaceutical company Stada Arzneimittel has acquired a portfolio of products from Takeda for $660 million.
The Global Drug Facility, which provides tuberculosis treatments to those in need in 150 countries, has listed a new drug to its product catalogue.
Allergan has reached a $750 million deal to resolve antitrust litigation brought against its subsidiary Forest Laboratories over Alzheimer’s drug Namenda.
Swiss pharmaceutical company Novartis has filed a patent infringement lawsuit against three Indian rivals in a US federal court over proposed generics of its heart failure drug Entresto.